サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541322

骨粗鬆症治療薬の市場レポート：製品タイプ、投与経路、地域別、2024～2032年

Osteoporosis Drugs Market Report by Product Type, Route of Administration, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 141 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.40円
骨粗鬆症治療薬の市場レポート：製品タイプ、投与経路、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 141 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の骨粗鬆症治療薬の市場規模は2023年に166億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに243億米ドルに達し、2024～2032年の間に4.2％の成長率（CAGR）を示すと予測しています。

骨粗鬆症は、骨組織と強度の劣化を引き起こす疾患です。骨粗鬆症は、X線、コンピュータ断層撮影（CT）、磁気共鳴画像法（MRI）など、さまざまな試験を行うことで診断されます。現在、骨粗鬆症の症状を緩和するために、通常の錠剤から静脈注射まで、さまざまな製剤の薬剤が販売されています。これらの薬剤は、骨吸収と骨形成のバランスを回復させ、骨の微細な欠陥を修復し、骨折のリスクを減らし、患者の全筋力を向上させるのに役立ちます。

座りっぱなしのライフスタイル、アルコールの過剰摂取、タバコの使用量の増加などを背景に骨粗鬆症の有病率が高まっていることが、市場の成長を後押しする主要要因となっています。セリアック病、腎臓病、肝臓病、がん、ループス、多発性骨髄腫、関節リウマチを患う人の増加は、市場の成長をさらに加速させています。さらに、骨量の減少は加齢とともに増加し、高齢者の骨粗鬆症発症リスクを高める。その結果、高齢者人口の増加は、世界の骨粗鬆症治療薬の需要にプラスの影響を与えています。さらに、いくつかの規制当局が新規治療の開発を進めており、これが市場の成長に寄与しています。例えば、米国食品医薬品局（FDA）は、骨折のリスクが高い閉経後女性や他の骨粗鬆症治療薬に不耐容の女性のための新規骨粗鬆症治療薬を承認しました。これに加えて、後期臨床試験段階にある薬剤が幅広く存在することが、今後数年間の市場成長を促進すると予想されます。

本レポートで扱う主要質問

  • 骨粗鬆症治療薬の市場の世界市場規模は？
  • 2024～2032年の世界の骨粗鬆症治療薬の市場の予想成長率は？
  • 世界の骨粗鬆症治療薬の市場を牽引する主要因は何か？
  • 世界の骨粗鬆症治療薬の市場に対するCOVID-19の影響は？
  • 世界の骨粗鬆症治療薬の市場の製品タイプ別内訳は？
  • 世界の骨粗鬆症治療薬の市場の投与経路別の内訳は？
  • 骨粗鬆症治療薬の市場の世界における主要地域は？
  • 世界の骨粗鬆症治療薬の市場における主要参入企業/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の骨粗鬆症治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品タイプ別

  • ビスフォスフォネート
  • カルシトニン
  • ランクリガンド阻害剤
  • 副甲状腺ホルモン療法（PTH）
  • 選択的エストロゲン受容体モジュレーター（SERM）
  • スクレロスチン阻害剤
  • その他

第7章 市場内訳：投与経路別

  • 経口
  • 注射
  • その他

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amgen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Radius Health Inc.
    • Teva Pharmaceutical Industries Ltd.
    • UCB S.A.
図表

List of Figures

  • Figure 1: Global: Osteoporosis Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Osteoporosis Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Osteoporosis Drugs Market: Breakup by Product Type (in %), 2023
  • Figure 4: Global: Osteoporosis Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 5: Global: Osteoporosis Drugs Market: Breakup by Region (in %), 2023
  • Figure 6: Global: Osteoporosis Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 7: Global: Osteoporosis Drugs (Bisphosphonates) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Osteoporosis Drugs (Bisphosphonates) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Osteoporosis Drugs (Calcitonin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Osteoporosis Drugs (Calcitonin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Osteoporosis Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Osteoporosis Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Osteoporosis Drugs (Injectable) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Osteoporosis Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: North America: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: North America: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: United States: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: United States: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Canada: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Canada: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Asia-Pacific: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Asia-Pacific: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: China: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: China: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Japan: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Japan: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: India: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: India: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: South Korea: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: South Korea: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Australia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Australia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Indonesia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Indonesia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Europe: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Europe: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Germany: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Germany: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: France: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: France: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: United Kingdom: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: United Kingdom: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Italy: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Italy: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Spain: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Spain: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Russia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Russia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Latin America: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Latin America: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Brazil: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Brazil: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Mexico: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Mexico: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Middle East and Africa: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Middle East and Africa: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Middle East and Africa: Osteoporosis Drugs Market: Breakup by Country (in %), 2023
  • Figure 76: Global: Osteoporosis Drugs Industry: SWOT Analysis
  • Figure 77: Global: Osteoporosis Drugs Industry: Value Chain Analysis
  • Figure 78: Global: Osteoporosis Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Osteoporosis Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Osteoporosis Drugs Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: Osteoporosis Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Osteoporosis Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Osteoporosis Drugs Market: Competitive Structure
  • Table 6: Global: Osteoporosis Drugs Market: Key Players
目次
Product Code: SR112024A3104

The global osteoporosis drugs market size reached US$ 16.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.2% during 2024-2032.

Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.

The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global osteoporosis drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type and route of administration.

Breakup by Product Type:

Bisphosphonates

Calcitonin

Rank Ligand Inhibitor

Parathyroid Hormone Therapy (PTH)

Selective Estrogen Receptor Modulators (SERMs)

Sclerostin Inhibitor

Others

Breakup by Route of Administration:

Oral

Injectable

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.

Key Questions Answered in This Report

  • 1. How big is the global osteoporosis drugs market?
  • 2. What is the expected growth rate of the global osteoporosis drugs market during 2024-2032?
  • 3. What are the key factors driving the global osteoporosis drugs market?
  • 4. What has been the impact of COVID-19 on the global osteoporosis drugs market?
  • 5. What is the breakup of the global osteoporosis drugs market based on the product type?
  • 6. What is the breakup of the global osteoporosis drugs market based on the route of administration?
  • 7. What are the key regions in the global osteoporosis drugs market?
  • 8. Who are the key players/companies in the global osteoporosis drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Osteoporosis Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Bisphosphonates
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Calcitonin
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Rank Ligand Inhibitor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Parathyroid Hormone Therapy (PTH)
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Selective Estrogen Receptor Modulators (SERMs)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Sclerostin Inhibitor
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Amgen Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Eli Lilly and Company
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 F. Hoffmann-La Roche AG
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 SWOT Analysis
    • 13.3.4 GlaxoSmithKline Plc
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Merck & Co. Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Novartis AG
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Pfizer Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Radius Health Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Teva Pharmaceutical Industries Ltd.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 UCB S.A.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis